Dr Reddy’s Steps Up Biosimilars And GLP-1 Investments As Semaglutide Launch Nears
Dr Reddy’s Laboratories is stepping up investments in biosimilars and GLP-1 therapies as it prepares for multiple launches, including semaglutide, across India and key international markets. While pricing pressure and a decline in lenalidomide sales weighed on profitability in the December quarter, growth in India, Europe and emerging markets helped cushion the impact. With semaglutide and the abatacept biosimilar emerging as near-term drivers, the company is sharpening its focus on portfolio execution and scale across markets where it already has a strong presence. M.V. Ramana, CEO – Branded Markets (India and Emerging Markets), outlines how Dr Reddy’s is positioning its pipeline to navigate shifting market dynamics and upcoming patent expiries.
Dr Reddy’s Laboratories is stepping up investments in biosimilars and GLP-1 therapies as it prepares for multiple launches, including semaglutide, across India and key international markets. While pricing pressure and a decline in lenalidomide sales weighed on profitability in the December quarter, growth in India, Europe and emerging markets helped cushion the impact.
With semaglutide and the abatacept biosimilar emerging as near-term drivers, the company is sharpening its focus on portfolio execution and scale across markets where it already has a strong presence. M.V. Ramana, CEO – Branded Markets (India and Emerging Markets), outlines how Dr Reddy’s is positioning its pipeline to navigate shifting market dynamics and upcoming patent expiries.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
